Eckert & Ziegler Q3/2017: Continually high income. Net liquidity exceeds € 50 million.
2017-11-09 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a Berlin-based company specializing in isotope technology for medical, scientific and industrial applications, increased its earnings per share by 63% to € 2.32 in the first nine months compared with the prior year’s period. The main reasons for the sales increase were stable growth in the Devices division of the Radiopharma segment and the first sales generated by the Gamma-Service Group acquired at the end of May. Excluding the discontinued operations and therewith according to the requirements under IFRS 5, earnings per share rose to € 1.72, increasing compared with the prior year’s quarter by € 0.22 per share or 14.7 %.
At € 100.4 million, Group sales were 12 % above the prior year’s level of € 89.5 million at the end of the third quarter of 2017. The main reasons for the sales increase were stable growth in the Devices division of the Radiopharma segment and the first sales generated by the Gamma-Service Group acquired at the end of May. Currency effects had no impact on sales. Organic, real sales growth – in other words, sales adjusted for currency effects and excluding the acquisitions and disposals made in 2016 and 2017 – came to € 5.4 million. Excluding the adjustments required under IFRS 5, the Group recorded total sales of € 106.6 million in the third quarter of 2017, compared with € 103.1 million in the prior year’s period.
The Radiopharma segment continues to be the growth driver. If the discontinued Cyclotron division is excluded, year-on-year growth was € 5.0 million or 32 %. In the USA in particular, the company further increased its year-on-year sales. Sales in the Radiation Therapy segment rose by € 0.4 million or 3% to € 18.3 million. The newly acquired Gamma-Service Group is included in the Isotope Products segment. The sales generated by the products and services of the newly acquired companies played a key part in enabling this segment to also increase its year-on-year sales by € 5.5 million or 9 % to € 63.7 million.
Cash flow increased faster than earnings, causing net liquidity – in other words, cash and cash equivalents less total liabilities to banks – to rise by € 25.3 million to € 50.2 million.
As a result of the extraordinary income from the sale of the Cyclotron division, earnings of around € 2.80 per share are forecast for 2017, € 0.60 of which is due to extraordinary effects and discontinued operations. Sales of approximately € 140 million are expected.
The complete financial statements can be viewed here:
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 760 employees, is one the world’s largest providers of isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
For further information or questions, please contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel. +49 (0) 30 / 94 10 84-138, firstname.lastname@example.org, www.ezag.com